The global psoriasis treatment market is projected to expand at a compound annual growth rate (CAGR) of 8.5% by 2026. Key factors fueling this growth include the rising prevalence of psoriasis, ...

Icotrokinra, a targeted oral peptide that selectively binds the interleukin-23 receptor, is under investigation for the ...

The greatest rate of treatment persistence in patients with psoriasis following MACE was seen in those receiving biologics vs other treatment types.

More than 50% of patients with psoriasis are eligible for systemic treatment, and nearly 90% would switch to an effective oral therapy with a favorable safety profile.

Approximately 5 million persons in the United States have psoriasis.1 Most have mild disease covering less than 3% of body-surface area, but approximately one fifth have more extensive involvement ...

The use of interleukin (IL)-23 inhibitors plays an important role in treating patients with psoriasis, as well as in treating ...

Biologic therapy use among patients with psoriatic disease was associated with a lower risk for malignancy compared with topical therapy use.

The only recommendation for management of this disease is prescription creams. However, a new study has discovered that switching to a Mediterranean diet could provide significant relief, according to ...

Psoriasis can feel like an uninvited guest that shows up on your skin and refuses to leave. Those red, scaly patches—often ...

On World Psoriasis Day 2025, know how stress may spark flare-ups of Psoriasis, why the link matters, and what you can do to ...